Archives
RNA m6A in Plant–Virus Antagonism
2026-09-15
The reference study identifies RNA m6A modification as a dynamic battleground between plants and Cucumber mosaic virus (CMV). It shows that plant methyltransferases mark viral RNA for ECT8-dependent destabilization, while the CMV 2b protein disrupts the methyltransferase machinery and alters host m6A regulation.
M344 in Neuroblastoma: From Chromatin to Phenotype
2026-09-14
M344 is a cell-permeable histone deacetylase inhibitor whose value extends beyond a single potency number. This article connects chromatin remodeling with neuroblastoma phenotypes and proposes an evidence-led assay strategy for interpreting cytostasis, apoptosis, differentiation, and combination responses.
Wnt agonist 1 for Wnt Signaling Assays
2026-09-14
Wnt agonist 1 (BML-284) provides a controllable chemical entry point for β-catenin/TCF pathway studies, from reporter assays and differentiation models to mechanistic cancer research. This workflow connects pathway activation with the Wnt/NR2F2/GPX4 chemoresistance hypothesis while emphasizing controls, dose design, and interpretation limits.
NAD+ and AMPK: Rethinking Energy-Stress Assays
2026-09-13
A translational framework for using Nicotinamide Adenine Dinucleotide (NAD+) to distinguish redox chemistry, enzymatic activity, and autophagy signaling in energy-stress research. By integrating recent AMPK–ULK1 findings, this article shows why NAD+ measurements should support—not substitute for—mechanistic pathway validation.
Making Neuroprotection Measurable After ICH
2026-09-12
A translational framework for connecting PI3K/AKT-linked neuroprotection after intracerebral hemorrhage with rigorous live/dead measurement using the Live-Dead Cell Staining Kit I (Calcein AM/PI).
BMX-IN-1: From Kinase Target to Lysosome Assay
2026-09-12
BMX-IN-1 is an irreversible BMX kinase inhibitor for connecting kinase signaling with lysosomal acidification and intracellular tuberculosis biology. This article provides a mechanism-led framework for choosing controls, interpreting phospho-signaling data, and separating host-directed promise from experimental proof.
Gemcitabine HCl: Reliable Cytotoxicity Assays
2026-09-11
This scenario-driven guide explains how Gemcitabine HCl, SKU A1402, can support reproducible DNA replication inhibition and in vitro cytotoxicity testing. It connects formulation, assay design, dose interpretation, storage, and preclinical tumor monitoring to practical laboratory decisions.
M344 in Neuroblastoma: Mechanisms and Tumor Control
2026-09-11
The 2025 study by Brumfield and colleagues connects elevated HDAC expression in advanced neuroblastoma with a therapeutically actionable response to M344, including histone hyperacetylation, G0/G1 arrest, caspase-mediated cell death, and reduced tumor growth. Its combination and metronomic dosing experiments suggest that schedule and treatment context may be as important as single-agent activity in preclinical neuroblastoma models.
From Finger Citron Biology to qPCR Strategy
2026-09-10
A translational framework for converting network pharmacology and HepG2 validation into reproducible transcript-level evidence, using HotStart 2X Green qPCR Master Mix to clarify assay specificity, workflow design, and the limits of mechanistic interpretation.
SAR131675 Workflow for VEGFR-3 Assays
2026-09-10
Build reproducible VEGFR-3 signaling, lymphatic endothelial survival, migration, and tumor-model workflows with SAR131675. Its ATP-competitive selectivity supports pathway attribution, while careful formulation controls help distinguish VEGFR-3 biology from precipitation, vehicle effects, and general cytotoxicity.
Ziprasidone HCl: From Receptors to Translation
2026-09-09
Ziprasidone HCl offers translational researchers a distinctive bridge between dopaminergic and serotonergic pharmacology, formulation science, and tumor-metabolism research. This article examines how ziprasidone hydrochloride can be evaluated as both a neuroscience tool and a reported GOT1-directed oncology research compound, with emphasis on assay design, permeability, and evidence boundaries.
DDI2–NFE2L1 Control of Ferroptosis
2026-09-09
The reference study shows that ferroptosis disrupts proteasome function and activates a DDI2-dependent NFE2L1 feedback response that restores protein quality control. Genetic loss or chemical inhibition of DDI2, including with nelfinavir, weakens this adaptation and sensitizes cells to ferroptotic death, identifying the pathway as a mechanistically defined target for further cancer and cell-death research.
Tamoxifen as a Precision Switch for Translational Biology
2026-09-08
Tamoxifen is more than an estrogen-pathway reagent: it is a context-dependent mechanistic probe and a temporal control tool for translational biology. This article connects conditional genetics with new evidence on persistent GZMK-expressing CD8+ T cells in recurrent airway inflammation.
Metronidazole for Reliable Cell Assays
2026-09-07
A scenario-based guide to using Metronidazole (SKU B1976) in viability, proliferation, transporter, and antimicrobial research. It explains concentration planning, solvent controls, assay interpretation, and practical criteria for selecting a well-characterized research reagent.
M344 in Neuroblastoma: Mechanism and Tumor Control
2026-09-07
The 2025 study evaluates M344 as a histone deacetylase inhibitor for neuroblastoma and connects increased histone acetylation with G0/G1 arrest, caspase-mediated cell death, reduced migration, and tumor-growth control. Its preclinical contribution is the integration of molecular, cellular, comparative, and combination-treatment evidence, including improved outcomes with metronomic dosing and selected chemotherapy combinations.
604 records 8/41 page Previous Next First page 上5页 678910 下5页 Last page